The pan-PAD inhibitor Cl-amidine effectively suppressed colitis in DSS murine models, both prophylactically and therapeutically, reducing NET burden, lowering NET marker citrullinated histone H3, restoring barrier integrity and reducing mucosal inflammation mirrored in PAD4 knock-out phenotypes.153. The gene discussed is PADI4; the disease is colitis.